Background: Quantifying the BCR-ABL1 rearrangement is important for monitoring chronic myelogenous leukemia (CML). To standardize BCR-ABL1 quantification, the World Health Organization (WHO) established the first international genetic reference panel. Here, we compared the BCR-ABL1 levels determined using international scale (IS)-based commercially available assays. Methods: BCR-ABL1 transcripts were quantified using two IS-based assays. 10
, 10
-2 , 10 , 10 -5 and 10 -6 dilutions of the b3a2 positive RNA were used for evaluating linearity, precision, and limit of detection. Correlation of the assay was evaluated by using DNA obtained from CML patients carrying the BCR-ABL1 b3a2 and b2a2 types. Results: Both Ipsogen and Asuragen assays showed fine linearity with reasonable %CV. LOD of each assay was calculated as 0.003% for Ipsogen, and 0.005% for Asuragen. By comparing the results that were lower than 10% by either one of the assay, Ipsogen and Asuragen results showed an overall good linear correlation with a tendency
Introduction
Quantification of BCR-ABL1 fusion transcripts is important for monitoring treatment response in chronic myeloid leukemia (CML) patients. Reaching a major molecular response (MMR), which is defined as a 3-log reduction of the BCR-ABL1 transcript level from a standardized baseline at diagnosis, by 18 months of imatinib treatment could be critical for CML patients since it is associated with favorable survival outcome [1] . This concept started from the IRIS study, where three reference laboratories shared 30 newly diagnosed samples and defined the baseline level as 100% on the international scale (IS) [2] . Since then, application of the internationally agreed scale for quantification of BCR-ABL1 transcript levels has been recommended [3] [4] [5] , and by using sample exchange programs with the reference laboratories that participated in the IRIS study, local institutions have decreased the interlaboratory variability by using the laboratory-specific conversion factors [6] . In 2010, the World Health Organization (WHO) established the first international genetic reference for the quantification of BCR-ABL1 transcripts [7] , and this standard material was used as the primary reference for the calibration of secondary standards in commercial assays [8] .
Here, we validated the analytical performance of two BCR-ABL1 transcript-monitoring assays based on the IS reporting system.
Materials and methods
BCR-ABL1 transcripts were quantified using two commercial kits: the BCR-ABL1 Mbcr FusionQuant Kit (Ipsogen SA, Marseille, France), and BCR-ABL1 Quant RUO Assay (Asuragen Inc., Austin, TX, USA). The Ipsogen and Asuragen assays both used ABL1 as a control gene and transcript levels were quantified according to the IS.
For analytical performance of each clinical assays, BCR/ABL b3a2 RNA dilution set (Invivoscribe, San Diego, CA, USA) that consists 10
, 10 -5 and 10 -6 dilutions of the b3a2 positive RNA diluted into negative control RNA were used for evaluating linearity, precision, and limit of detection. Three replicates of each concentration and a negative control were tested using two IS-based assays for 3 individual days by a single technologist, leading to a total of nine replicates of each concentration to be analyzed.
Correlation of the two assays were evaluated using a total of 61 patient samples found to be positive by nested PCR performed in Molecular Diagnostic Laboratory, Seoul National University Hospital between September 2011 and July 2012. RNA was extracted using the High Pure RNA Isolation Kit (Roche Applied Science, Mannheim, Germany). There were 49 samples carrying the b3a2 type and 12 samples carrying the b2a2 type. The ABL1 copy numbers were qualified in all samples according to the guideline [9] . The transcript levels of patient samples quantified by each assay were compared directly without using the log scale. Regression analysis and calculation of correlation coefficients were obtained by both methods and the Bland and Altman estimations were also employed. Limit of detection (LOD) was calculated using probit analysis of SPSS for Windows statistical package (v 15.0.1).
Results
Both Ipsogen and Asuragen assays showed fine linearity with R 2 of 0.9871 by Ipsogen and 0.9966 by Asuragen ( Figure 1 ). All levels of log reduction showed CVs of under 20% (Table 1 ). All nine negative samples were negative by both assays. LOD of each assay was calculated as 0.003% for Ipsogen, and 0.005% for Asuragen.
When 61 patient samples were analyzed by the Ipsogen and Asuragen assays, the results demonstrated poor linear correlation between the two methods (R 2 = 0.3743). The scatter plot showed clear division into subgroups according to the transcript types ( Figure 2) ; therefore, we analyzed the samples of b3a2 and b2a2 subtypes separately. Among the 49 samples of b3a2 subtype, nine samples had transcript levels below the detection limit by the Asuragen and four by the Ipsogen assays. Three samples were found to be below the detection limit by both assays. In six samples, BCR-ABL1 transcripts were detected by the Ipsogen but not by the Asuragen assay, whereas BCR-ABL1 transcripts were detected by the Asuragen but not by the Ipsogen assay in only one sample. There were no agreement between Ipsogen and Asuragen results with regard to MMR in six samples: the Ipsogen assay showed that these samples had b3a2 transcripts above the MMR level (0.1% IS), whereas the Asuragen results showed that they were below the MMR level (Table 2) .
By comparing the results that were lower than 10%IS by either one of the assay, it seemed that Ipsogen and Asuragen results showed an overall good linear correlation (R 2 = 0.9232) (Figure 2) , with a tendency for the Ipsogen assay to show slightly higher b3a2 levels than the Asuragen assay ( Figure 3A) . The proportional bias and the constant bias of -0.32%IS was were observed in the BlandAltman plot, though the constant bias was not considered to be statistically significant since the 95% confidence interval contained zero. The proportional bias was also observed when Asuragen's ARQ IS calibrator panel for b3a2 was analyzed by both Ipsogen and Asuragen assays.
These methods were also compared by quantification of b2a2 transcript levels in 12 samples. None were below the detection limit of the Asuragen or Ipsogen assays. The Ipsogen and Asuragen assays showed good linear correlation (R 2 = 0.9962) (Figure 2) , with a tendency of Asuragen showing higher values than the Ipsogen ( Figure 3B ). Only one sample showed a discrepant result with regard to achieving MMR, wherein the Asuragen showed b2a2 levels above and the Ipsogen showed b2a2 levels below MMR (data not shown).
Discussion
Quantification of BCR-ABL1 transcript levels at 3, 6, and 12 months after the start of imatinib treatment is known as an important factor for predicting clinical outcomes for CML patients. In particular, the 3-month transcript level is considered as the most important prognostic factor, irrespective of the imatinib treatment dose [10] . A recent report indicated the importance of the BCR-ABL1 transcript doubling time when assessing the dynamics of CML relapse [11] , suggesting that evaluation of BCR-ABL1 levels is essential for monitoring the response to the drug. On quantification with the two IS-based assays, comparison between the two commercially available IS-based BCR-ABL1 assays showed good quantitative correlation in separate analysis of BCR-ABL1 subtypes, but with a tendency of Ipsogen assay having a bias for showing higher values than the Asuragen assay in b3a2 transcripts, leading to some discrepancies occurring at the levels near MMR. The b2a2 transcripts showed the opposite tendency; however, the b2a2 sample size was limited for obtaining conclusive evidence. This difference between the subtypes might be due to the fact that the first international genetic reference material established by the WHO for the quantification of BCR-ABL1 transcripts was obtained using the K562 cell line, which carries the b3a2 subtype. Consequently, only b3a2 transcripts are truly qualified for comparative testing, and the conversion factor for b2a2 should be provided separately. In case of Asuragen assay, conversion factors for b3a2 and b2a2 can be separately calculated and can be applied to patient samples with known subtype, though manufacturers recommend that using over-arching CP for both transcripts is the best approach. On the other hand, Ipsogen does not provide separate conversion factor for b2a2.
In conclusion, the two commercially available IS-based BCR-ABL1 assays showed an overall good quantitative correlation. It should be taken into consideration that each assay tended to produce higher values than the other, depending on the BCR-ABL1 subtypes, suggesting that a separate conversion factor for each subtype can be more helpful when BCR-ABL1 transcript levels are converted into IS. 
